ANI Historical Financial Ratios
| ANIP Stock | USD 65.50 0.31 0.47% |
ANI Pharmaceuticals is presently reporting on over 113 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0012, PTB Ratio of 2.37 or Days Sales Outstanding of 101 will help investors to properly organize and evaluate ANI Pharmaceuticals financial condition quickly.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. About ANI Financial Ratios Analysis
ANI PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate ANI Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on ANI financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across ANI Pharmaceuticals history.
ANI Pharmaceuticals Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing ANI Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on ANI Pharmaceuticals sales, a figure that is much harder to manipulate than other ANI Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is ANI Pharmaceuticals dividend as a percentage of ANI Pharmaceuticals stock price. ANI Pharmaceuticals dividend yield is a measure of ANI Pharmaceuticals stock productivity, which can be interpreted as interest rate earned on an ANI Pharmaceuticals investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Most ratios from ANI Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into ANI Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.At this time, ANI Pharmaceuticals' PFCF Ratio is relatively stable compared to the past year. As of 06/28/2025, EV To Operating Cash Flow is likely to grow to 25.38, while PTB Ratio is likely to drop 2.37.
| 2022 | 2023 | 2024 | 2025 (projected) | Dividend Yield | 0.002484 | 0.001637 | 0.001522 | 0.001194 | Price To Sales Ratio | 2.07 | 2.04 | 1.74 | 1.65 |
ANI Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
ANI Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ANI Pharmaceuticals fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Price To Sales Ratio | 1.67 | 2.69 | 2.07 | 2.04 | 1.74 | 1.65 | |
| Ptb Ratio | 3.43 | 1.78 | 1.62 | 1.93 | 2.17 | 2.37 | |
| Days Sales Outstanding | 167.72 | 217.05 | 190.86 | 121.52 | 131.73 | 100.62 | |
| Book Value Per Share | 16.36 | 28.48 | 20.82 | 25.42 | 22.18 | 22.5 | |
| Operating Cash Flow Per Share | 1.28 | 0.26 | (1.92) | 6.61 | 3.31 | 3.48 | |
| Stock Based Compensation To Revenue | 0.0621 | 0.0485 | 0.0461 | 0.0424 | 0.0478 | 0.0454 | |
| Capex To Depreciation | 1.53 | 0.5 | 0.28 | 0.31 | 0.25 | 0.24 | |
| Pb Ratio | 3.43 | 1.78 | 1.62 | 1.93 | 2.17 | 2.37 | |
| Ev To Sales | 4.13 | 2.52 | 3.55 | 2.82 | 2.17 | 2.39 | |
| Free Cash Flow Per Share | (4.43) | (1.61) | (2.93) | 5.58 | 2.44 | 2.56 | |
| Roic | (0.0352) | (0.0361) | (0.029) | 0.0584 | 4.43E-4 | 4.65E-4 | |
| Inventory Turnover | 1.43 | 1.23 | 1.32 | 1.63 | 1.83 | 1.96 | |
| Net Income Per Share | (1.88) | (3.38) | (2.95) | 1.04 | (0.96) | (1.01) | |
| Days Of Inventory On Hand | 254.63 | 296.37 | 277.08 | 223.6 | 199.53 | 182.58 | |
| Payables Turnover | 7.74 | 4.38 | 4.74 | 4.95 | 5.48 | 5.06 | |
| Research And Ddevelopement To Revenue | 0.0768 | 0.0526 | 0.0705 | 0.0704 | 0.0726 | 0.0689 | |
| Capex To Revenue | 0.33 | 0.11 | 0.052 | 0.038 | 0.0276 | 0.0262 | |
| Cash Per Share | 0.66 | 7.96 | 2.97 | 12.28 | 7.83 | 7.43 | |
| Pocfratio | 22.76 | 174.72 | (20.96) | 8.34 | 16.68 | 9.45 | |
| Interest Coverage | (1.7) | (2.73) | (0.89) | 1.74 | 0.0332 | 0.0348 | |
| Capex To Operating Cash Flow | 0.6 | 4.48 | 7.12 | (0.53) | 0.26 | 0.25 | |
| Pfcf Ratio | (6.55) | (28.57) | (13.73) | 9.88 | 22.69 | 23.82 | |
| Days Payables Outstanding | 47.16 | 83.32 | 77.07 | 73.76 | 66.6 | 63.27 | |
| Income Quality | (0.68) | (0.078) | 0.65 | 6.33 | (3.46) | (3.28) | |
| Ev To Operating Cash Flow | 34.4 | 231.03 | (28.6) | 8.89 | 24.17 | 25.38 | |
| Pe Ratio | (15.41) | (13.62) | (13.66) | 52.86 | (57.66) | (54.77) | |
| Return On Tangible Assets | (0.0838) | (0.0948) | (0.0997) | 0.0281 | (0.0272) | (0.0285) | |
| Ev To Free Cash Flow | (9.9) | (37.78) | (18.73) | 10.52 | 32.87 | 34.52 | |
| Earnings Yield | (0.0649) | (0.0734) | (0.0732) | 0.0189 | (0.0173) | (0.0182) | |
| Intangibles To Total Assets | 0.48 | 0.4 | 0.42 | 0.37 | 0.26 | 0.47 | |
| Net Debt To E B I T D A | 6.12 | (111.09) | 4.96 | 0.61 | 6.05 | 6.36 | |
| Current Ratio | 3.04 | 2.17 | 3.68 | 3.46 | 2.72 | 2.59 | |
| Tangible Book Value Per Share | 0.3 | 2.92 | 3.61 | 12.24 | (8.97) | (8.52) | |
| Receivables Turnover | 2.18 | 1.68 | 1.91 | 3.0 | 2.77 | 2.63 |
Pair Trading with ANI Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ANI Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ANI Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against ANI Stock
| 0.44 | GRAL | GRAIL, LLC | PairCorr |
| 0.36 | FBRX | Forte Biosciences | PairCorr |
| 0.35 | A | Agilent Technologies | PairCorr |
| 0.33 | ATNFW | CannBioRx Life Sciences | PairCorr |
The ability to find closely correlated positions to ANI Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ANI Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ANI Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ANI Pharmaceuticals to buy it.
The correlation of ANI Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ANI Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ANI Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ANI Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.